These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 36264574

  • 21. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
    Fu EL, Patorno E, Everett BM, Vaduganathan M, Solomon SD, Levin R, Schneeweiss S, Desai RJ.
    Eur Heart J; 2023 Jun 25; 44(24):2216-2230. PubMed ID: 37259575
    [Abstract] [Full Text] [Related]

  • 22. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chiang FT, Tu YK.
    Eur J Endocrinol; 2023 Jul 20; 189(1):S17-S25. PubMed ID: 37474112
    [Abstract] [Full Text] [Related]

  • 23. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P, CVD-REAL Investigators and Study Group*.
    Circulation; 2017 Jul 18; 136(3):249-259. PubMed ID: 28522450
    [Abstract] [Full Text] [Related]

  • 24. Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study.
    Tesfaye H, Wang KM, Zabotka LE, Wexler DJ, Schmedt N, Koeneman L, Seman L, Paik JM, Patorno E.
    J Gen Intern Med; 2024 Aug 18; 39(10):1870-1879. PubMed ID: 38710868
    [Abstract] [Full Text] [Related]

  • 25. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN.
    J Manag Care Spec Pharm; 2021 Apr 18; 27(4):455-468. PubMed ID: 33769850
    [Abstract] [Full Text] [Related]

  • 26. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.
    McCormick N, Yokose C, Lu N, Wexler DJ, Aviña-Zubieta JA, De Vera MA, McCoy RG, Choi HK.
    JAMA Intern Med; 2024 Jun 01; 184(6):650-660. PubMed ID: 38619822
    [Abstract] [Full Text] [Related]

  • 27. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
    McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP.
    JAMA Cardiol; 2021 Feb 01; 6(2):148-158. PubMed ID: 33031522
    [Abstract] [Full Text] [Related]

  • 28. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY, Liu SY, Yin DG.
    Medicine (Baltimore); 2021 Jul 30; 100(30):e26431. PubMed ID: 34397684
    [Abstract] [Full Text] [Related]

  • 29. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
    Paik JM, Tesfaye H, Curhan GC, Zakoul H, Wexler DJ, Patorno E.
    JAMA Intern Med; 2024 Mar 01; 184(3):265-274. PubMed ID: 38285598
    [Abstract] [Full Text] [Related]

  • 30. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
    Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, Poulter NR, Pratley RE, Thomsen AB, Buse JB, LEADER Trial Investigators.
    J Am Coll Cardiol; 2020 Mar 17; 75(10):1128-1141. PubMed ID: 32164886
    [Abstract] [Full Text] [Related]

  • 31. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
    Svanström H, Ueda P, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B.
    Lancet Diabetes Endocrinol; 2019 Feb 17; 7(2):106-114. PubMed ID: 30527909
    [Abstract] [Full Text] [Related]

  • 32. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
    Wexler DJ, de Boer IH, Ghosh A, Younes N, Bebu I, Inzucchi SE, McGill JB, Mudaliar S, Schade D, Steffes MW, Tamborlane WV, Tan MH, Ismail-Beigi F, GRADE Research Group.
    JAMA Intern Med; 2023 Jul 01; 183(7):705-714. PubMed ID: 37213109
    [Abstract] [Full Text] [Related]

  • 33. Heart failure hospitalisation relative to major atherosclerotic events in type 2 diabetes with versus without chronic kidney disease: A meta-analysis of cardiovascular outcomes trials.
    Sacre JW, Magliano DJ, Shaw JE.
    Diabetes Metab; 2021 Sep 01; 47(5):101249. PubMed ID: 33744399
    [Abstract] [Full Text] [Related]

  • 34. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 Sep 01; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

  • 35. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Shavadia JS, Zheng Y, Green JB, Armstrong PW, Westerhout CM, McGuire DK, Cornel JH, Holman RR, Peterson ED.
    Am Heart J; 2019 Dec 01; 218():92-99. PubMed ID: 31715435
    [Abstract] [Full Text] [Related]

  • 36. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
    Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P, CVD-REAL Investigators and Study Group.
    J Am Coll Cardiol; 2018 Jun 12; 71(23):2628-2639. PubMed ID: 29540325
    [Abstract] [Full Text] [Related]

  • 37. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, Lambelet M, Lawatscheck R, Bakris GL, Ruilope LM, Agarwal R.
    JACC Heart Fail; 2022 Nov 12; 10(11):860-870. PubMed ID: 36328655
    [Abstract] [Full Text] [Related]

  • 38. Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
    Nyström T, Toresson Grip E, Gunnarsson J, Casajust P, Karlsdotter K, Skogsberg J, Ustyugova A, EMPRISE Study Group.
    Diabetes Obes Metab; 2023 Jan 12; 25(1):261-271. PubMed ID: 36097728
    [Abstract] [Full Text] [Related]

  • 39. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N, CARMELINA Investigators.
    Circulation; 2019 Jan 15; 139(3):351-361. PubMed ID: 30586723
    [Abstract] [Full Text] [Related]

  • 40. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    GRADE Study Research Group, Nathan DM, Lachin JM, Bebu I, Burch HB, Buse JB, Cherrington AL, Fortmann SP, Green JB, Kahn SE, Kirkman MS, Krause-Steinrauf H, Larkin ME, Phillips LS, Pop-Busui R, Steffes M, Tiktin M, Tripputi M, Wexler DJ, Younes N.
    N Engl J Med; 2022 Sep 22; 387(12):1075-1088. PubMed ID: 36129997
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.